Skip to main content
. 2021 Jul 12;11:14324. doi: 10.1038/s41598-021-93498-w

Figure 1.

Figure 1

Study design and number of patients in each phase. Discovery and replication phases were conducted within the ISSYS cohort (patients with hypertension, aged 50–70, and without dementia and stroke at the baseline visit). In both phases of the study, progression of WMH was defined as a total RPS score greater than or equal to 3. In the discovery phase, cases and controls were matched by age, sex, and baseline WMH burden, while in the replication phase, cases and controls were matched by age and sex. Parts of this figure were supported by Servier Medical Art (https://smart.servier.com/) with permission under the Creative Commons Attribution 3.0 Unported License. The figure was constructed using Microsoft Office Powerpoint 365 (version 2013, https://www.microsoft.com/en-us/microsoft-365/powerpoint), GNU image manipulation software (GIMP, version 2.10.22, https://www.gimp.org/) and ‘ggplot’ library (version 3.3.2, https://ggplot2.tidyverse.org/) included in R software. (R version 3.6.3, 2020-02-29; 2020 The R Foundation for Statistical Computing, https://www.r-project.org/). ASAH2, neutral ceramidase; ISSYS, Investigating Silent Strokes in hYpertensives Study; MET, hepatocyte growth factor receptor; MMP9, matrix metalloproteinase-9; RPS, Rotterdam progression scale; WMH, white matter hyperintensities.